Missing data in trial-based cost-effectiveness analysis: the current state of play
Missing data in trial-based cost-effectiveness analysis: the current state of play
复制标题
DOI：
10.1002/hec.1693
复制
发表时间：
2012-02-01
期刊：
影响因子：
2.1
通讯作者：
Tilling, Kate
中科院分区：
文献类型：
--
作者：
Noble, Sian Marie;Hollingworth, William;Tilling, Kate
基于随机对照试验（RCT）的成本-效果分析在医疗技术评估中越来越多地使用，但容易出现数据缺失。这突出表明需要采取适当的方法处理缺失数据。本文回顾了自2003年以来基于RCT的成本效果分析中使用的缺失数据方法。完整的个案分析可能会导致不适当的结论，但它仍然是最流行的方法，而且随着时间的推移，这种方法的使用越来越多，成本效益分析中数据缺失的程度往往报告得不好，方法往往不清楚。报告缺失的数据敏感性分析将提高文章的透明度。版权所有（C）2010约翰威利父子有限公司
Randomised controlled trial (RCT)-based cost-effectiveness analyses, which are prone to missing data, are increasingly used in healthcare technology assessment. This has highlighted the need for appropriate methodological approaches to the handling of missing data. This paper reviews missing data methodology used in RCT-based cost-effectiveness analyses since 2003. Complete case analysis, which may lead to inappropriate conclusions, is still the most popular approach and its use has increased with time.The degree of missing data in cost-effectiveness analyses was often poorly reported and the methodology was often unclear. Reporting of missing data sensitivity analyses would improve article transparency. Copyright (C) 2010 John Wiley & Sons, Ltd.